Affiliation:
1. Department of Biotechnology, Jaypee Institute of Information Technology, NOIDA, U.P., India
Abstract
Cancer is a global concern leading to millions of deaths every year. A declining trend in new drug
discovery and development is becoming one of the major issues among the pharmaceutical, biotechnology industries
and regulatory agencies. New drug development is proven to be a very lengthy and a costly process.
Launch of a new drug takes 8-12 years and huge investments. Success rate in oncology therapeutics is also low
due to toxicities at the pre-clinical and clinical trials level. Many oncological drugs get rejected at very promising
stage showing adverse reactions on healthy cells. Thus, exploring new therapeutic benefits of the existing,
shelved drugs for their anti-cancerous action could result in a therapeutic approach preventing the toxicities
which occurs during clinical trials. Drug repurposing has the potential to overcome the challenges faced via
conventional way of drug discovery and is becoming an area of interest for researchers and scientists. Although
very few in vivo studies are conducted to prove the anti-cancerous activity of the drugs. Insufficient in vivo animal
studies and lack of human clinical trials are the lacuna in the field of drug repurposing. This review focuses
on the aspect of drug repurposing for cancer therapeutics. There are various studies which show that drugs
approved for clinical indications other than cancer have shown promising anti-cancer activities. Some of the
commonly used drugs like Benzodiazepines (Diazepam, Midzolam), Antidepressants (Imipramine, Clomipramine,
and Citalopram), Antiepileptic (Valporic acid, Phenytoin), Anti diabetics (metformin) etc., have been reported
to show potential activity against the cancerous cells.
Publisher
Bentham Science Publishers Ltd.
Subject
Drug Discovery,Pharmacology
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献